Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is approximately 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of $101 to a low of sixty one dolars.
From its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The Long or retail Term Care segment has selling of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, healthcare control capabilities. The Corporate segment involves in providing administrative services and management. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.